Year after year, month after month, week after week, the British Association for Psychopharmacology [BAP] has invited psychiatrists, and psychiatrists in training, to their “educational meetings”. Throughout my career I heard my Consultant colleagues ‘swear by’ these educational meetings. I never once attended. This post shares an archive that seeks to explain why.
What follows is my correspondence with the British Association of Psychopharmacology [BAP]. It is almost a decade long. I share this archive – that has never before been seen – in the hope that it might offer some learning from the past.
BAP meetings require accreditation from the Royal College of Psychiatrists. It is important to note that if a doctor fails to attend sufficient 'accredited' education [to gather sufficient points] that she/he will not be revalidated [and so will be unable to continue as a prescribing doctor]
From: Dr Peter J Gordon
Sent: 13 January 2013
To: BAP [British Association for Psychopharmacology]
Subject: Clinical practice with anti-dementia drugs: a revised (second) consensus statement from BAP
Dear Susan Chandler,
My name is Dr Peter J. Gordon, I am an Old Age Psychiatrist working in NHS Forth Valley. My GMC number is 3468861.
I am interested in researching potential Conflict of Interests. Would you be able to provide the BAP file for such interests for this paper. Stephen Whitehead, the Chief Executive of the Association of the British Pharmaceutical Industry has confirmed in several publications that such information is open to all.
Yours sincerely,
Peter Gordon
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology John T O'Brien and Alistair Burns DOI: 10.1177/0269881110387547 Expenses associated with the meeting were in part defrayed by charges relating to pharmaceutical companies who sent representatives to the meeting and had the opportunity to comment on the evidence presented but who were not part of the writing group (Lundbeck, Pfizer, Eisai). Contributors at the consensus meeting each provided a declaration of interest of potential conflict in line with BAP and Journal of Psychopharmacology policy. These are held on file at the BAP Office. BAP Executive Officer, Susan Chandler, BAP Office, Cambridge, UK (susan@bap.org.uk).
From: Dr Peter J Gordon
Sent: 19 June 2013
To: BAP
Subject: Request for [Scanned]
Dear Susan,
Please could you forward all the DECLARATIONS of INTEREST for this paper:
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology, John T O’Brien & Alistair Burns J Psychopharmacol published online 18 November 2010
Yours sincerely,
Dr Peter J Gordon
From: BAP
Sent: 21 June 2013
Subject: RE: Request for [Scanned]
Dear Dr Gordon
Thank you for your email. I would be happy to send you the relevant Declarations of Interest for the BAP Consensus Meeting. However I am out of the office at a BAP meeting today, and will then leave for a week of holiday. I will be back in the office on Monday 1 July and will send you the material then.
Yours sincerely
Susan Chandler
Mrs Susan Chandler
Executive Officer
British Association for Psychopharmacology
36 Cambridge Place, Hills Road, Cambridge CB2 1NS
Tel (direct): 01223 358 428
Fax: 01223 321 268
http://www.bap.org.uk
The British Association for Psychopharmacology is registered in England as a Private Company No 5866899.
From: BAP
Sent: 15 July 2013
Dear Dr Gordon
My apologies for the delay but please find attached the Declarations of Interest for the BAP Dementia Consensus Meeting held in 2010. Please let me know if you require any further information.
Yours sincerely
Susan Chandler [BAP]
From: Dr Peter J Gordon
Sent: 17 July 2013
To :BAP
Subject: BAP declaration – Professor Alistair Burns – CONSENSUS MEETING of 28 Jan 2010
Dear Susan,
I am confused – Professor Burns in his declaration for this meeting of the 28 January 2010 states “I am National Clinical Director for Dementia in England (and NHS England since April 2013)”
I can only assume that Professor Burns only recently gave his declaration for this meeting of January 2010.
This is quite worrying to me as it potentially casts doubt on the BAP process, timely probity and promised transparency in printed article of this date: medications that this consensus considered in 2010.
I hope you can clarify my confusion.
Yours sincerely
Dr Peter Gordon
From: BAP
Sent: 07 August 2013
Dear Dr Gordon
The Declarations of Interest were completed by the participants prior to the consensus meeting in January 2010. When I received your request I sent the document to the meeting organisers, Professors Burns and O’Brien out of courtesy, for their information. Professor Burns simply suggested that for completeness I could add “(and NHS England since April 2013)”.
I hope that this clarifies your confusion.
Yours sincerely
Susan Chandler
From: Peter J Gordon
Sent: 07 August 2013
To: BAP
Cc: Professor Alistair Burns
Dear Susan,
Many thanks indeed for this clarification. It is unusual, I would suggest, and certainly post-hoc, to add this declaration (which to me is not a conflict of interest) when these declarations were specifically for the meeting on 28th January 2010.
I remain concerned, not about conflicts of interest, but that complete transparency of such interests may be promised (ABPI code) but is not a reality. Until we get a Sunshine Act, Key Opinion Leaders have only to follow this guidance and no duty to declare financial transactions. NHS Trusts and Boards may or may not have Hospitality Registers and FOI returns (certainly in Scotland’s 22 NHS Boards) reveal that payments to healthcare workers from the Pharmaceutical Industry are generally not declared.
We know (from ABPI) that in the UK, last year, the Pharmaceutical Industry paid £40 million to UK doctors/healthcare workers. I wonder how much went to Key Opinion Leaders, such as nearly all of those attending the BAP meeting of January 2010? This is a legitimate question, I think.
I am grateful for your help and kindness.
Aye Peter Gordon
TWO YEARS ON
From: Dr Peter J Gordon
Sent: 05 May 2015
To: BAP
Subject: Declarations of Interest (BAP members)
Dear BAP,
It is very good to find that the British Association for Psychopharmacology has a clear tab on all pages to declaration of interest form and that the BAP guidance on this is explicit.
I am hoping you might be able to help me. I write as I have petitioned the Scottish Government for a Sunshine Act and so I have a wide interest in governance of transparency.
I was wondering where the public can access all BAP declarations? Do BAP have an online database of all submissions?
If you do not have an electronic publicly available database, do BAP intend to have one? What is the current BAP policy on declarations for all members and can this policy be shared?
If you do not have a database can you supply to me all declarations given (for every year since BAP required declarations to be made) for the following key opinion leaders. When inquiring about governance and public transparency of financial interests I have been copying in Niall Dickson, CEO of the General Medical Council [GMC]. I do this as the GMC has repeatedly confirmed how seriously they take this matter.
- Professor Allan Young
- Professor Peter Passmore
- Professor Guy Goodwin
- Professor Philip J Cowen
- Professor David Nutt
- Professor J Chick
- Professor David Taylor (pharmacist)
- Professor Clive Ballard
- Professor Nick Fox
I do hope that you may be able to help with this inquiry.
Yours sincerely,
Dr Peter J Gordon
From: BAP
Sent: 06 May 2015
Subject: RE: Declarations of Interest (BAP members)
Dear Dr Gordon
I am about to leave Cambridge to run a BAP conference until the end of the week but will reply to your email more fully in due course.
Susan Chandler
Mrs Susan Chandler
Executive Officer
British Association for Psychopharmacology
From: Dr Peter J Gordon
Sent: 08 October 2015
To: BAP
Subject: Declaration to BAP by Dr Stephen Stahl
Dear Ms Chandler,
Please could you send to me by return the Declaration of Interests as submitted by Stephen Stahl to BAP.
Please could you also provide the employment and contact details of “Mr Rick Davis”
Yours sincerely
Dr Peter J Gordon
GMC number: 3468861
BAP: “A robust learning environment for healthcare professionals”
From: BAP
Sent: 12 October 2015
Subject: RE: Declaration to BAP by Dr Stephen Stahl
Dear Dr Gordon
The sessions at the BAP meeting which included Dr Stahl and Mr Davis were organised by Sunovion Pharmaceuticals as part of their support for the event.
We require a Declaration of Interest only from those who submit an abstract for the conference.
I have forwarded your request to Sunovion.
Yours sincerely
Susan Chandler
The British Association for Psychopharmacology is registered in England as a Private Limited Company No. 5866899. Registered Charity No. 277825.
Stephen Stahl: $3,581,159 in payments from Pharma
From: Dr Peter J Gordon
Sent: 15 October 2015
To: SUNOVION Ltd
Subject: RE: Mr Rick Davis information
Dear SUNOVION,
Thank you, this is helpful.
Why was it not made clear on the programme that Mr Rick Davis was an employee of Arbor Scientia?
Please can you confirm how much Dr Stahl was paid by Sunovion for this CME approved talk given in “partnership” with BAP.
Was this exact amount made clear to:
- The audience
- The British public
Professor Stahl stated in the BAP programme that his day-long, BAP key-note address, was part of a “robust educational environment”
Dollars for Docs provides evidence that Dr Stahl seems to have omitted.
Dr Stahl has received more than $3.5 million dollars from the pharmaceutical industry in the last two years
Yours sincerely,
Dr Peter J Gordon
Note: 15 October 2015:
The programme of the 2015 BAP “summer Meeting” had no declarations of interest within it.
From: Dr Peter J Gordon
Sent: 15 October 2015
To: BAP
Subject: Financial Declarations of interest: open to public, in pounds and pence, for all time
Dear Susan,
I write further to recent communications regarding the recent CME-accredited “summer Meeting” where BAP in “partnership” with SUNOVION facilitated a full day [CME] educational talk by Stephen Stahl.
Where can the UK public find out how much Stephen Stahl was paid for this CME?
Why was it not made clear in the BAP Programme that Mr Rick Davis is the CEO of Arbor Scientia?
Would you agree that the ABPI “Central Platform”, to start next year, is unlikely to provide any greater transparency?
Yours sincerely,
Dr Peter J Gordon
Lurasidone – financial conflicts of interest
From: Dr Peter J Gordon
Sent: 09 April 2016
To: ‘nicola.sturgeon.msp@scottish.parliament.uk’ <nicola.sturgeon.msp@scottish.parliament.uk>; ‘shona.robison.msp@scottish.parliament.uk’ <shona.robison.msp@scottish.parliament.uk>; ‘Paul.Gray@gov.scot’ <Paul.Gray@gov.scot>; ‘occe@gmc-uk.org’ <occe@gmc-uk.org>; ‘fgodlee@bmj.com’ <fgodlee@bmj.com>; ‘Wessely, Simon’ <simon.wessely@kcl.ac.uk>
Cc: ‘angiolina.foster@nhs.net’ <angiolina.foster@nhs.net>; ‘alastair.cook@lanarkshire.scot.nhs.uk’ <alastair.cook@lanarkshire.scot.nhs.uk>; ‘Alex Neil’ <Alex.Neil.msp@scottish.parliament.uk>; ‘acurrie@rcpsych.ac.uk’ <acurrie@rcpsych.ac.uk>; ‘Ben Goldacre’ <ben@badscience.net>; ‘ben.goldacre@phc.ox.ac.uk’ <ben.goldacre@phc.ox.ac.uk>; ‘Billy Watson’ <billy.watson@samh.org.uk>; ‘Catherine.Fergusson@scottish.parliament.uk’ <Catherine.Fergusson@scottish.parliament.uk>; ‘Chris.Hynd@scottish.parliament.uk’ <Chris.Hynd@scottish.parliament.uk>; ‘Carl Reynolds’ <carl.reynolds@openhealthcare.org.uk>; ‘David Carroll’ <carroll.davide@gmail.com>; ‘catherine.calderwood@gov.scot’ <catherine.calderwood@gov.scot>; ‘cabinetsecretaryforhealthandwellbeing@scotland.gsi.gov.uk’ <cabinetsecretaryforhealthandwellbeing@scotland.gsi.gov.uk>; ‘colin.mckay’ <colin.mckay@mwcscot.org.uk>; ” <colin.brown3@scotland.gsi.gov.uk>; ‘DGHSC@gov.scot’ <DGHSC@gov.scot>; ‘De Felice Michelle (HEALTHCARE IMPROVEMENT SCOTLAND)’ <michelle.defelice@nhs.net>; ‘; ‘david.mcqueen@nhs.net’ <david.mcqueen@nhs.net>; ‘dhall2@nhs.net’ <dhall2@nhs.net>; ‘denise.coia@nhs.net’ <denise.coia@nhs.net>; ‘Duncan McNeil’ <Duncan.McNeil.msp@scottish.parliament.uk>; ‘David.Torrance.msp@scottish.parliament.uk’ <David.Torrance.msp@scottish.parliament.uk>; ‘FirstMinister@scotland.gsi.gov.uk’ <FirstMinister@scotland.gsi.gov.uk>; ‘Gordon.Clark@gov.scot’ <Gordon.Clark@gov.scot>; ‘hello@scottishhumanrights.com’; ‘hcharles@gmc-uk.org’ <hcharles@gmc-uk.org>; ‘Iain.Wallace@lanarkshire.scot.nhs.uk’; ‘irene.graham@nhs.net’ <irene.graham@nhs.net>; ‘Jackson.Carlaw.msp@scottish.parliament.uk’ <Jackson.Carlaw.msp@scottish.parliament.uk>; ‘John.Wilson.msp@scottish.parliament.uk’ <John.Wilson.msp@scottish.parliament.uk>; ‘jane.grant9@nhs.net’ <jane.grant9@nhs.net>; ‘Jason.Leitch@scotland.gsi.gov.uk’ <Jason.Leitch@scotland.gsi.gov.uk>; ‘Jenny Marra’ <jenny.marra.msp@scottish.parliament.uk>; ‘Macrae Jacqui (HEALTHCARE IMPROVEMENT SCOTLAND)’ <jacqueline.macrae@nhs.net>; ‘Kathryn.Fergusson@gov.scot’ <Kathryn.Fergusson@gov.scot>; ‘Kenny.MacAskill.msp@scottish.parliament.uk’ <Kenny.MacAskill.msp@scottish.parliament.uk>; ‘Kirsty.Gough@scottish.parliament.uk’ <Kirsty.Gough@scottish.parliament.uk>; ‘kaddie@rcpsych.ac.uk’ <kaddie@rcpsych.ac.uk>; <Kezia.Dugdale.msp@scottish.parliament.uk>; ‘Kate Fearnley’ <Kate.Fearnley@mwcscot.org.uk>; <Katrina.Thomson@mwcscot.org.uk>; ‘Lknifton@mentalhealth.org.uk’ <Lknifton@mentalhealth.org.uk>; ‘lmclay@nhs.net’ <lmclay@nhs.net>; ‘linda.bickerton@scottishhealthcouncil.org’ <linda.bickerton@scottishhealthcouncil.org>; ‘margaret mccartney’ <mgtmmccartney@gmail.com>; ‘Mitchell Tracey (HEALTHCARE IMPROVEMENT SCOTLAND – SD039)’ <traceymitchell3@nhs.net>; ‘Maureen Watt’ <maureen.watt.msp@scottish.parliament.uk>; ‘medicaldirector.tayside@nhs.net’ <medicaldirector.tayside@nhs.net>; ‘Neil.Findlay.msp@scottish.parliament.uk’ <Neil.Findlay.msp@scottish.parliament.uk>; ‘nigel.henderson@penumbra.org.uk’ <nigel.henderson@penumbra.org.uk>; ‘Office of Alex Salmond’ <alex.salmond@snp.org>; ‘petitions@scottish.parliament.uk’ <petitions@scottish.parliament.uk>; ‘paul.gray@scotland.gsi.gov.uk’ <paul.gray@scotland.gsi.gov.uk>; ‘richard.norris@scottishhealthcouncil.org’ <richard.norris@scottishhealthcouncil.org>; ‘Richard.Simpson.msp@scottish.parliament.uk’ <Richard.Simpson.msp@scottish.parliament.uk>; ‘Ruth.Davidson.msp@scottish.parliament.uk’ <Ruth.Davidson.msp@scottish.parliament.uk>; ‘Roderick Campbell’ <Roderick.Campbell.msp@scottish.parliament.uk>; ‘rhona.morrison@nhs.net’ <rhona.morrison@nhs.net>; ‘robbie.pearson@nhs.net’ <robbie.pearson@nhs.net>; ‘Sharon Davies’ <sdavies@bmj.com>; ‘Scottish Law Reporters’ <scottishlawreporters@gmail.com>; ‘sign@sign.ac.uk’ <sign@sign.ac.uk>; ‘Stephen Lawrie’ <S.Lawrie@ed.ac.uk>; ‘Scotland@changingfaces.org.uk’ <Scotland@changingfaces.org.uk>; ‘scottish.ministers@scotland.gsi.gov.uk’ <scottish.ministers@scotland.gsi.gov.uk>; ‘stimimi@talk21.com’ <stimimi@talk21.com>; ‘susan@bap.org.uk’ <susan@bap.org.uk>; ‘Taylor, Mark’ <Mark.Taylor@nhslothian.scot.nhs.uk>; ‘tracey.gillies@nhs.net’ <tracey.gillies@nhs.net>; ‘Tim Stokes’ <tim.stokes@otago.ac.nz>; ‘Toni. Giugliano@samh. org. uk’ <Toni.Giugliano@samh.org.uk>; ‘Willie.Rennie.msp@scottish.parliament.uk’ <Willie.Rennie.msp@scottish.parliament.uk>
Subject: Sunshine Act for Scotland [PE1493]
Saturday 9th April 2016
Dear all,
This petition has now been closed. The consultation with the Scottish public demonstrated support for a Sunshine Act.
The following link gives a full account of the two years of my own time given to the principle of transparency.
The Scottish Public want Sunshine
Given that my petition was about openness I am sharing this with those involved in the process.
2016 BAP Summer Meeting
Diary Note by Dr Peter J Gordon, 31 August 2016: Paid opinion leaders, many well known to me for their direct links with Pharma, networking with the young professionals of today and tomorrow.
These photographs were removed by BAP sometime after 31 August 2019. However a few screenshots were captured, as follows:
BMJ submission: 1st September 2016 by Dr Peter J. Gordon [the BMJ did not publish this]
“Rising stars”: British Association of Psychopharmacology, 2016, Summer Conference
The published photographs of the recent British Association of Psychopharmacology (BAP) 2016 Summer Conference [1] returned my thoughts to Braillon [2] and Matheson [3].
At this BAP conference, an accredited CPD conference, the “rising stars” are seen to mix with today’s ‘key opinion leaders’. A number of established ‘key opinion leaders’ have declared their financial interest with ABPI [4]
I support transparency [5]. I have always understood that this can only ever be a means to an end.
Robert K Merton once insisted that science should be based not on interest but “disinterest”.
Returning to the 2016 BAP conference: I fully welcome the sharing of experiences between generations. I am however concerned that at such conferences there may not be any of the correspondents that I most value [6]
References:
[1] http://www.simoncallaghanphotography.com/Brighton-Photographer-Blog/Conference/BAP/Summer-Meeting-2016
[2] Transparency: A tricky smoke screen
[3] Ghostwriting: the importance of definition and its place in contemporary drug marketing
[4] ABPI database
[5] A Sunshine Act for Scotland
[6] The contributions of those “retired” often prove invaluable
Competing interest: I have campaigned for a Sunshine Act for Scotland. As a scientist I support research, development and innovation.
From: Peter J Gordon
Sent: 06 September 2016
To: NHS Scotland Psychiatrist and colleague
Subject: Lanarkshire Symposium 2016
I see that Professor Allan Young is giving one of the sponsored talks and that Lundbeck are sponsoring two other speakers. A good programme but you will not be surprised that I will not be going.
I have heard Prof Allan Young speak. It would seem that he is paid by industry and [by my reckoning] promotes their products very well indeed. He is also Chair of the RCPsych Psychopharmacology Committee and President Elect of BAP.
aye Peter
From: Peter J Gordon
Sent: 18 October 2016
To: BAP
Subject: Clinical Practice with Anti-Dementia Drugs: Updated Guidelines from the BAP
Dear BAP,
Where can the public access declarations of interest for those involved in this Guideline and its presentation?
If you could send me this link I would be most grateful.
If there is no link can you please send me by return the declarations of all those involved.
Yours sincerely,
Dr Peter Gordon
Consultant Psychiatrist for Older Adults
St John’s Hospital, Livingston.
From: BAP
Sent: 19 October 2016
Subject: RE: Clinical Practice with Anti-Dementia Drugs: Updated Guidelines from the BAP
Dear Dr Gordon
The Declarations of Interest will be available to the public when the new Guideline document is uploaded to the BAP website.
Yours sincerely
Susan Chandler
Executive Officer
British Association for Psychopharmacology
From: Peter J Gordon
Sent: 19 October 2016
To: BAP
Copied to Professor Simon Wessley, President of the Royal College of Psychiatrists
Dear Mrs Chandler,
That is good to know. But what I am looking for now is the declarations of interest for all those involved – as per substantive BAP policy.
All BAP declarations should be open to the public. As you are aware I have raised this matter with you a number of times over the years and yet little, if any meaningful progress towards transparency has been made by BAP.
Please can you provide the declarations of interest by return. If not I will consider taking wider action in the in full public light.
Kind wishes
Dr Peter Gordon
Consultant Psychiatrist for Older Adults
From: Dr Peter J Gordon
Sent: 24 April 2017
To: Professor Simon Wessley, President of the Royal College of Psychiatrists
Subject: relationships between UK Psychiatry and ‘big business’
“puritanical”
“all in the past”
These statements about UK psychiatry and the pharmaceutical industry were published by the RCPsych in your time as President.
Simon, you have not publically supported a Sunshine Act. Why not?
[I feel a need to tell you that I worry about over-regulation] [however a single central register of financial interests would be cost efficient]
Aye Peter Gordon
Subject: Educational Teaching for Psychiatry, NHS West Lothian – 23rd May 2017
Hi Peter,
Thanks for expressing your views. Unfortunately it is proving almost impossible to get people to speak at Tuesday teaching so in order to keep it going I have opened it up to drug reps, as at least they are willing to speak!! It is always announced ahead of the teaching so people can decide whether they want to come or not.
Many thanks,
CME Course organiser
Sent: 23 May 2017
To: all NHS Lothian Pychiatrists in training, shared by an NHS Lothian Trainer
Subject: BAP Online CPD Resource
BAP Online CPD Resource
Does your trainee use the BAP online CPD resource? If not, why not – it’s free for trainees!
BAP is frequently contacted to find out if there is any way it can support the psychopharmacological education of trainee psychiatrists. Given that one of the main aims of BAP is to increase clinicians’ knowledge and expertise in psychopharmacology, this is an issue that the Association is keen to help in any way it could. As a result, BAP teamed up with the Royal College of Psychiatrists to provide our online resource free of charge to any trainee who is subscribed to the College’s TrOn (which is also free). To date, the BAP’s online resource has been used by around one in four consultants or SAS grade psychiatrists in the UK. Now, this high quality and constantly updated reference and training material can be used to help trainees develop the knowledge and skills in psychopharmacology that will be essential to their future careers.
If your trainee is not a subscriber, now is the time to encourage them to take up this unprecedented educational offer. Direct your trainees to this resource
Professor Hamish McAllister-Williams
BAP Director of Education
P.S. Are you a subscriber for the BAP online resource? It has been specifically designed to provide a broad and comprehensive coverage of psychopharmacology that complements the BAP face to face meetings such as the Masterclasses and Certificate modules.
P.P.S. Did you know that the cheapest way to subscribe to the BAP online resource (just £30/year for effectively one of the most comprehensive textbooks of psychiatry available) is if you are a subscriber to the College CPD online. There are also several other cost-effective options for subscribing to the BAP online resource.
Continuing Medical “Education”
From: NHS Lothian Psychiatrists and those in training
Sent: 26 May 2017
Subject: BAP Online CPD Resource
No need to look at this unless interested. It is a look at BAP education and its relationship with industry.
aye Peter
Dr Peter J Gordon
GMC number 3468861
From: NHS Lothian Consultant Psychiatrist
Sent: 26 May 2017
Subject: BAP Online CPD Resource
Good to be reminded that info we get, even via well thought of providers, needs to be looked at very sceptically
26 July 2017, diary note:
It depresses me looking at these celebratory galleries of photos from this summer’s BAP Meeting
Last year there was a similar set of BAP galleries for the 2016 summer meeting. I wrote a carefully worded BMJ Rapid Response about this but the BMJ did not publish it as a rapid response.
From: Peter J Gordon
Sent: 01 November 2017
To: the Royal College of Psychiatrists
Dear Professional Practice and Ethics Committee,
I am writing to express concern about the level of competing financial interests in the overall membership of the RCPsych Psychopharmacology Committee.
Evidence has demonstrated that such financial competing interests can lead to doctors recommending worse treatments for patients:
I am also concerned about the close working relationship between RCPsych and the British Association for Psychopharmacology (BAP) in terms of educating UK psychiatrists and trainees. For the same evidence-based reasons as above.
I would urge the RCPsych to address this issue meaningfully and look forward to a response that I hope the RCPsych will share with the public on the RCPsych website.
Kind wishes,
Dr Peter J Gordon
GMC number 3468861
From: an Educational Supervisor for NHS Lothian
Sent: 16 January 2018
Subject: BAP and Medical Education
Feels daunting that such things need to be questioned before face value acceptance.
From: an NHS Colleague
Sent: 03 April 2018
I’m attending the BAP masterclass course (3 days) later this month and I was really excited about it. I thought they would give me the answers to some tricky medication issues. I’ll be honest, I never thought to really check their links to pharma or what they have declared regarding accepting industry money. I’ll have to keep an eye out for that….
Diary note: BAP Educational Meetings for 2018 are “FULLY BOOKED”
- Prof Oliver Howes (Co-ordinator/speaker Day A – Schizophrenia)
- Prof Peter Haddad/Prof Hamish McAllister-Williams (Co-ordinators/speakers Day B – Bipolar/Perinatal/ADHD)
- Prof David Baldwin/Prof Hamish McAllister-Williams (Co-ordinators/speakers Day c – Depression/Anxiety/Sleep)
Hole Ousia posts that may refer to, or include material on, the British Association for Psychopharmacology
Current BAP advice on competing financial interests:
